EyeCRO conducts successful pre-IND meeting with US Food and Drug Administration to discuss CsA-MIDROPS™

ByPhotoreceptor

EyeCRO recently requested and conducted a pre-IND meeting with the US FDA to discuss the nonclinical and clinical development plans for CsA-MiDROPS™ to treat Dry Eye Disease. The agency was supportive of the project and agreed that the proposed nonclinical and CMC studies would allow entry into a phase II clinical trial. Also discussed was the potential and required clinical endpoints for examining CsA-MiDROPS™ in patients with uveitis. EyeCRO expects to file the IND by Q1 of 2020 and begin enrolling patients.

Similar Posts

Retinal microvascular changes associated with disability in daily activities among older adults

ByConnor Hodde

Retinal microvascular changes appear to be associated with development of disability in performing activities of daily living among older adults, and retinal signs may be useful in predicting outcomes among this population, according to a report published Online First by Archives of Ophthalmology. http://medicalxpress.com/news/2011-11-retinal-microvascular-disability-daily-older.html

EyeCRO joins Novo Nordisk, Novartis, Sanofi, Merck KGaA Darmstadt Germany, Lundbeck, and Leo Pharma to prioritize animal welfare in scientific research by signing the Marseille Declaration

ByConnor Hodde

“Toward enhancing ethical practices in scientific research, EyeCRO has joined several industry-leading companies to sign the “Marseille Declaration”, the first joint pharmaceutical industry declaration on animal housing and use.” Click here to read the full press release

Bio Matters: Family influences led eyecro’s executive into scientific research

ByConnor Hodde

Rafal Farjo, Ph.D. is chief operating officer of both eyecro and Charlesson, which are involved in research to advance treatments for eye disease such as age-related macular degeneration, diabetic retinopathy and ocular inflammation. Far from resisting his family’s interest in all things STEM — science, technology, engineering and math — Farjo embraced it. “I loved it, and…

Mayo Clinic work shows possible Lucentis side effect

ByConnor Hodde

At the Amercian Academy of Opthalmology 115th Annual Meeting, findings were presented from a retrospective study conducted after a Mayo Clinic opthalmologist noticed an increase in intraoccular pressure (IOP) in her patients using Genentech’ (Roche) Lucentis (ranibizumab), an FDA-approved drug for the treatment of age-related macular degeneration (AMD). MARINA (Minimally Classic/OccultTrial of the Anti-Vascular Endothelial…

Cell transplant restores sight in mice

ByConnor Hodde

Experimental cell transplants can improve the sight of visually impaired mice, it has been widely reported. The Independent called the research behind the news a “major step towards cure for blindness”, while The Guardian said the work is “the first demonstration that cell transplants can restore useful vision”. During the research, scientists used mice bred…

Fat gives nanoparticles a fighting chance

ByConnor Hodde

Inhalable and thermo-responsive, fat-encased nanoparticles have been developed by researchers at the University of Sydney as possible treatment for lung cancer. The team has recently designed inhalable, targetable particles that can attack tumors but leave healthy cells undamaged, reducing the side effects of cancer treatment. The particles consist of a drug encased in a lipid…